The purpose of this study is to measure the change in hemoglobin A1c (HbA1c) with LY3457263 compared with placebo in participants with type 2 diabetes who are not at HbA1c goal when treated with a stable dose of semaglutide or tirzepatide. Participation in the study will last about 9 months.
Have type 2 diabetes
Have HbA1c ≥7.5% to ≤10.5% at screening
Have a body mass index (BMI) of ≥27 kilograms per square meter (kg/m2) at screening
Have had a stable body weight for the three months prior to screening
Have type 1 diabetes, latent autoimmune diabetes, or history of ketoacidosis or hyperosmolar coma
Have a prior or planned surgical treatment for obesity
acute myocardial infarction
cerebrovascular accident (stroke)
Eli Lilly and Company
Lead sponsor